High grade glioma: Imaging combined with pathological grade defines management and predicts prognosis

Radiotherapy and Oncology

Volumn 85, Issue 3, 2007, Pages 371-378

  Burnet, Neil G ^a   Lynch, Andrew G ^b   Jefferies, Sarah J ^c   Price, Stephen J ^b   Jones, Phil H ^d   Antoun, Nagui M ^e   Xuereb, John H ^b   Pohl, Ute ^f  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Oncology Centre   (Belgium)

^d HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

^e Hutchison MRC Research Centre ^*

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Glioma; High grade; Imaging; Pathology; Prognosis

Indexed keywords

KI 67 ANTIGEN; TEMOZOLOMIDE;

ADULT; AGGRESSION; ARTICLE; CANCER GRADING; CANCER PATIENT; CELL DEATH; CELL PROLIFERATION; CLINICAL FEATURE; DEATH; DIAGNOSTIC IMAGING; GLIOBLASTOMA; HAZARD; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OLIGODENDROGLIA; OUTCOME ASSESSMENT; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIOLOGY; SURVIVAL;

BRAIN NEOPLASMS; GLIOBLASTOMA; GLIOMA; HUMANS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 36849085992     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.10.008     Document Type: Article

References (30)

1. Athanassiou H., Synodinou M., Maragoudakis E., et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23 (2005) 2372-2377
2. Bailey P., and Cushing H. A classification of tumours of the glioma group (1926), Philadelphia, Lippincott
3. Bleehen N.M., and Stenning S.P. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council brain tumour working party. Br J Cancer 64 (1991) 769-774
4. Burger P.C., Vogel F.S., Green S.B., and Strike T.A. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56 (1985) 1106-1111
5. Burger P.C., and Green S.B. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59 (1987) 1617-1625
6. Burnet N.G., Bulusu V.R., and Jefferies S.J. Management of primary brain tumours. In: Booth S., and Bruera E. (Eds). Palliative care consultations in primary and metastatic brain tumours (2004), Oxford University Press, Oxford 1-30
7. Burnet N.G., Jefferies S.J., Benson R.J., Hunt D.P., and Treasure F.P. Years of life lost (YLL) from cancer is an important measure of population burden - and should be considered when allocating research funds. Br J Cancer 92 (2005) 241-245
8. Cairncross J.G., Ueki K., Zlatescu M.C., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90 (1998) 1473-1479
9. Cairncross G., Berkey B., Shaw E., et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol 24 (2006) 2707-2714
10. Cavenee W.K., Furnari F.B., Nagane M., et al. Diffusely infiltrating astrocytomas. In: Kleihues P., and Cavenee W.K. (Eds). World Health Organisation classification of tumours. Pathology and genetics of tumours of the nervous system (2000), IARC Press, Lyon 10-21
11. Collins V.P. Mechanisms of disease: genetic predictors of response to treatment in brain tumors. Nat Clin Pract Oncol 4 (2007) 362-374 Review
12. Daumas-Duport C., Scheithauer B., O'Fallon J., and Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer 62 (1988) 2152-2165
13. Deckert M., Reifenberger G., and Wechsler W. Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer Res Clin Oncol 115 (1989) 179-188
14. Fulling K.H., and Nelson J.S. Cerebral astrocytic neoplasms in the adult: contribution of histologic examination to the assessment of prognosis. Semin Diagn Pathol 1 (1984) 152-163
15. Grambsch P., and Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 8 (1994) 515-526
16. Kernohan J.W., and Sayre G.P. Tumors of the central nervous system. Atlas of tumor pathology, section X, fascicle 35 (1952), Armed Forces Institute of Pathology, Washington DC
17. Kim T.S., Halliday A.L., Hedley-Whyte E.T., and Convery K. Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg 74 (1991) 27-37
18. Kleihues P., Davis R.L., Coons S.W., and Burger P.C. Anaplastic astrocytoma. In: Kleihues P., and Cavenee W.K. (Eds). World Health Organisation classification of tumours. Pathology and genetics of tumours of the nervous system (2000), IARC Press, Lyon 27-28
19. Kleihues P., Burger P.C., Collins V.P., Newcomb E.W., Ohgaki H., and Cavenee W.K. Glioblastoma. In: Kleihues P., and Cavenee W.K. (Eds). World Health Organisation classification of tumours. Pathology and genetics of tumours of the nervous system (2000), IARC Press, Lyon 29-39
20. Kros J.M., Gorlia T., Kouwenhoven M.C., Zheng P.P., Collins V.P., Figarella-Branger D., et al. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 66 (2007) 545-551
21. Law M., Oh S., Johnson G., et al. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 58 (2006) 1099-1107
22. McLendon R.E., Enterline D.S., Tien R.D., et al. Tumours of central neuroepithelial origin. In: Bigner D.D., McLendon R.E., and Bruner J.M. (Eds). Russell and Rubinstein's pathology of tumours of the nervous system. 6th ed. (1998), Springer, London 308-571
23. Paulus W., and Peiffer J. Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer 64 (1989) 442-447
24. Price S.J., Jena R., Burnet N.G., Hutchinson P.J., Dean A.F., Pena A., et al. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. Am J Neuroradiol 27 (2006) 1969-1974
25. Reifenberger G., Kros J.M., Burger P.C., et al. Anaplastic oligodendroglioma. In: Kleihues P., and Cavenee W.K. (Eds). World Health Organisation classification of tumours. Pathology and genetics of tumours of the nervous system (2000), IARC Press, Lyon 62-64
26. Reifenberger G., Kros J.M., Burger P.C., et al. Anaplastic oligoastrocytoma. In: Kleihues P., and Cavenee W.K. (Eds). World Health Organisation classification of tumours. Pathology and genetics of tumours of the nervous system (2000), IARC Press, Lyon 68-69
27. Stupp R., Mason W.P., van den Bent M.J., et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
28. Stupp R., and Hegi M.E. Methylguanine methyltransferase testing in glioblastoma: when and how?. J Clin Oncol 25 (2007) 1459-1460
29. van den Bent M.J., Carpentier A.F., Brandes A.A., et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24 (2006) 2715-2722
30. In: Kleihues P., and Cavenee W.K. (Eds). World Health Organisation classification of tumours. Pathology and genetics of tumours of the nervous system (2000), IARC Press, Lyon